Results 121 to 130 of about 15,535 (172)

The role of Rwanda Field Epidemiology and Laboratory Training Program graduates and residents in response to the first Marburg Virus Disease outbreak in Rwanda. [PDF]

PLOS Glob Public Health
Ruseesa E, Hagabimana A, Ntirenganya F, Kinani P, Hinda R, Nshimiyimana E, Niyoyita C, Umutoni A, Stamatakis C, Mucunguzi HV, Rwagasore E.   +10 more
europepmc   +1 more source

Genomic and transmission dynamics of the 2024 Marburg virus outbreak in Rwanda. [PDF]

Nat Med
Butera Y, Mutesa L, Parker E, Muvunyi R, Umumararungu E, Ayitewala A, Musabyimana JP, Olono A, Sesonga P, Ogunsanya O, Kabalisa E, Adedokun O, Gahima N, Irankunda L, Mutezemariya C, Niyonkuru R, Uwituze A, Uwizera I, Kagame J, Umugwaneza A, Rwabuhihi J, Umwanankabandi F, Mbonitegeka V, Ntagwabira E, Kayigi E, Izuwayo G, Murenzi H, Mukankwiro T, Tuyiringire N, Uwimana JMV, Gasengayire A, Sindayiheba R, Onyeugo GU, Aragaw M, Gitundu L, Bigirimana R, Fallah M, Ejikeme A, Sembuche S, Kabanda A, Mugisha JC, Francis EES, Gashema P, Ndayisenga J, Rugamba A, Kanyabwisha F, Murenzi G, Happi A, Ngabonziza JCS, Gashegu M, Ahmed A, Bigirimana N, Rwagasore E, Semakula M, Rwabihama JP, Musanabaganwa C, Seruyange E, Nkeshimana M, Twagirumugabe T, Turatsinze D, Remera E, Gahamanyi N, Tessema SK, Mukagatare I, Nsanzimana S, Happi C, Muvunyi CM.   +66 more
europepmc   +1 more source

Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine. [PDF]

J Gen Virol
Pfranger M, Krause N, Asbach B, Meier J, Carnell G, Scheer L, Kalender A, Brenner D, Tonks P, Frost S, Wright E, Jordan I, Kennedy E, Hewson R, Blacklaws B, Chan A, Parthasarathy S, Dowall S, Carroll M, Sandig V, Fedosyuk S, Kinsley R, Heeney J, Wagner R.   +23 more
europepmc   +1 more source

Identification of potential VP40 inhibitor of Marburg virus through molecular docking, pharmacokinetic analysis and molecular dynamics simulation. [PDF]

Sci Rep
Das R, Bhattarai A, Tamang B, Thakur N.
europepmc   +1 more source

Process Intensification for Recombinant Marburg Virus Glycoprotein Production Using <i>Drosophila</i> S2 Cells. [PDF]

Eng Life Sci
Göbel S, Mayerlen L, Eiser IY, Fichtmueller L, Clements D, Reichl U, Genzel Y, Lehrer A.   +7 more
europepmc   +1 more source

Exploration of African natural products as VP35 inhibitors to combat Marburg virus infection: Molecular docking, molecular dynamics, and quantum mechanical computations. [PDF]

PLoS One
Abdelrahman AHM, Mekhemer GAH, Sidhom PA, El-Tayeb MA, Khan S, Ibrahim MAA.   +5 more
europepmc   +1 more source

Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda. [PDF]

Sci Rep
Mugisha JC, Kayigi E, Gahamanyi N, Uwayo HD, Umwanankabandi F, Gashema P, Rwagasore E, Turatsinze D, Nkeshimana M, Gashegu M, Ntagwabira E, Makayoto L, Ngabonziza JCS, Mukagatare I, Tuyishime A, Rujeni N, Mutesa L, Seruyange E, Musafiri S, Twagirumugabe T, Harelimana JD, Muvunyi CM.   +21 more
europepmc   +1 more source

Marburg virus disease Mayhem: A new threat emerges in Rwanda. [PDF]

New Microbes New Infect
Kumar P, Jayan J, Balaraman AK, Pandey S, Brar M, Mehta R, Sah S.   +6 more
europepmc   +1 more source

Seroprevalence of Marburg virus: A modeling study in endemic area. [PDF]

North Clin Istanb
Kleebayoon A, Wiwanitkit V.
europepmc   +1 more source